Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
N/A N=46 Be-Active Study - Increasing Physical Activity in Cancer Survivors
Physical Activity · Exercise · Cancer Survivors
Primary: Change in Physical Activity — 49.3; 15.1 minutes per week
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 1 N=84 A Study in Advanced Cancer
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
Phase 2 N=12 TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
Breast Cancer
Primary: The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion)…
Phase 2 N=12 Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Phase 2 N=20 Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Disease Control Rate — 25 percentage of participants
Phase 1 N=3 C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose
Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
N/A N=153 Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
N/A N=236 Telephone Support for Metastatic Breast Cancer Patients
Metastatic Breast Cancer
Primary: Fatigue Interference Subscale of Fatigue Symptom Inventory — 2.96; 3.66; 3.24; 3.43 units on a scale — p=.018
Phase 2 N=58 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
Phase 2 N=9 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
Solid Tumor · Anaplastic Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) of Cisplatin (Phase I) — 100 mg/m^2
Phase 2 N=1 Pioglitazone in Thyroid Cancers
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Primary: Tumor Response (Change) — 6.0; 3.9 cm
Phase 2 N=208 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Phase 2 N=6 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Anaplastic Thyroid Cancer
Primary: Overall Response (OR) — 0; 3; 3; 1 Participants
Phase 1 N=34 Cancer Vaccine Targeting Brachyury Protein in Tumors
Neoplasms · Malignant Solid Tumors · Colon Neoplasms
Primary: Number of Participants With Brachyury-Specific T-cell Responses — 1; 0; 4; 1 Participants
N/A N=303 Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Smoking Cessation
Primary: Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months — 29; 51 Participants
Phase 2 N=113 Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
Metastatic Androgen Independent Prostate Cancer
Primary: Safety of APC8015F by Review of Reported Adverse Events — 109 Participants
N/A N=4,322 Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System
Breast Cancer · Colorectal Cancer
Primary: Proportion of Complex Cancer Survivors Meeting Quality of Care Guidelines for Chronic Conditions and Follow-up Cancer Surveillance
N/A N=50 Acceptance and Commitment Therapy for Chronic Pain in Cancer Survivors
Chronic Pain
Primary: The Degree of Effectiveness of Acceptance and Commitment Therapy: [Impact] — 23.9; 21.4; 41.7; 37.5 units on a scale — p=0.82
Phase 2 N=3 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer · Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg
N/A N=6,400 Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
Early Cancer Detection
Primary: Study Data and Samples Were Used for CancerSEEK Assay Development — 712; 3870; 5; 14 Participants
Phase 2 N=62 Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or…
Phase 3 N=308 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Squamous Cell Carcinoma of the Anal Canal
Primary: Progression-free Survival (PFS) — 9.3; 7.4 months — p=0.0006